277.12
0.99 (0.36%)
| Previous Close | 276.13 |
| Open | 277.00 |
| Volume | 216,124 |
| Avg. Volume (3M) | 245,561 |
| Market Cap | 28,751,536,128 |
| Price / Earnings (TTM) | 62.70 |
| Price / Earnings (Forward) | 43.86 |
| Price / Sales | 5.39 |
| Price / Book | 5.89 |
| 52 Weeks Range | |
| Earnings Date | 5 Aug 2026 |
| Profit Margin | -9.40% |
| Operating Margin (TTM) | 0.99% |
| Diluted EPS (TTM) | -3.69 |
| Quarterly Revenue Growth (YOY) | 48.60% |
| Total Debt/Equity (MRQ) | 28.49% |
| Current Ratio (MRQ) | 1.96 |
| Operating Cash Flow (TTM) | 212.02 M |
| Levered Free Cash Flow (TTM) | -120.68 M |
| Return on Assets (TTM) | -3.22% |
| Return on Equity (TTM) | -11.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | BeOne Medicines Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 0.0 |
| Price Volatility | 1.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -4.0 |
| Average | -0.60 |
|
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 17.31% |
| % Held by Institutions | 43.94% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| LEE CHAN HENRY | - | 263.92 | -590 | -155,713 |
| OYLER JOHN | - | 263.92 | -3,693 | -974,657 |
| WANG LAI | - | 263.92 | -1,169 | -308,522 |
| WU XIAOBIN | - | 263.92 | -1,357 | -358,139 |
| Aggregate Net Quantity | -6,809 | |||
| Aggregate Net Value ($) | -1,797,031 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 263.92 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WANG LAI | Officer | 16 Jun 2026 | Sell (-) | 1,169 | 263.92 | 308,522 |
| LEE CHAN HENRY | Officer | 16 Jun 2026 | Sell (-) | 590 | 263.92 | 155,713 |
| OYLER JOHN | Officer | 16 Jun 2026 | Sell (-) | 3,693 | 263.92 | 974,657 |
| WU XIAOBIN | Officer | 16 Jun 2026 | Sell (-) | 1,357 | 263.92 | 358,139 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |